The difference between delivered and prescribed dialysate sodium in haemodialysis machines

Ali M. Shendi 1,2 and Andrew Davenport 2

1Nephrology Unit, Internal Medicine Department, Zagazig University, Zagazig, Egypt and 2Department of Nephrology, Royal Free Hospital, University College London, London, UK

ABSTRACT

Background. The choice of dialysate sodium (DNa) for haemodialysis (HD) patients remains controversial, with some studies reporting that a lower DNa improves blood pressure control and reduces intradialytic weight gain. Studies on DNa depend on the alignment of programmed to delivered DNas. We wished to determine whether there were differences between programmed and delivered DNas.

Methods. Dialysate samples were obtained from three dialysis machines: Fresenius 4008H (F4008H) and 5008S (F5008S) and B-Braun hemodiafiltration (HDF) Dialog + (BB). DNa was measured by indirect ion-selective electrode (ISE), flame photometry (FP) and ion chromatography (IC) at different DNa concentrations.

Results. We tested 18 F5008S, 18 F4008H and 31 BB machines over 153 HD treatments. The median measured minus programmed DNa was significantly greater with the BB machine [ISE, 7 (6–8); FP, 7 (6–8); IC, 6 (5–7)], followed by the F4008H [ISE, 5.5 (5–7); FP, 4 (2.25–5.75); IC, 4 (2–5)] and F5008S [ISE, 4 (2–5); FP, 1 (–1–1.75); IC, 1 (–0.5 to 2)] mEq/L (P < 0.05). At higher programmed DNAs (140–145 mEq/L), measured DNa was greater for the BB and F4008 machines by all methods (P < 0.05), but only by ISE for the F5008 (P < 0.05).

Conclusions. We noted a systematic bias in DNa delivery with measured DNas being greater than that programmed by our HD machines. The magnitude of the bias varied between machines and with DNa. Our results may help explain the diverse results reported in studies of DNAs.

Keywords: dialysate, flame photometry, haemodialysis, ion chromatography, sodium

INTRODUCTION

There is no current consensus for the optimal dialysate sodium (DNa) concentration for haemodialysis (HD) patients. Most dialysis patients gain sodium between HD sessions. Sodium removal is predominantly achieved by convection through ultrafiltration, although diffusion down a concentration gradient between serum and dialysate can additionally increase sodium losses. This diffusive clearance, due to the ‘sodium gradient’, determines the change in serum sodium concentration at the end of the HD session and falls in plasma osmolality [1]. Choosing a DNa concentration lower than serum sodium should result in a reduction in the prevalence of hypertension and interdialytic weight gain (IDWG), but with a potential increased risk of intradialytic hypotension and cramps, whereas the
opposite effects may accompany the choice of a DNA concentration greater than the serum concentration [2–10].

Data from the Dialysis Outcomes and Practice Patterns Study (DOPPS) reported that higher DNA prescriptions were associated with increased IDWG on the order of 0.17% of post-dialysis weight (or 0.12 kg for a 70-kg patient) per 2 mEq/L (mmol/L) higher DNA [11]. In addition, the DOPPS also reported that the average pre-dialysis systolic blood pressure was lower in dialysis facilities that individualized DNA compared with those dialysis centers using a standard DNA for all patients [11]. Individualized DNA prescription using a patient’s pre-dialysis serum sodium as a reference is thus considered by many as the ideal standard [2, 12–14]. However, the standard laboratory method of measuring serum sodium, using an indirect ion-selective electrode (ISE), can be affected by high glucose, lipid and protein concentrations [15].

What is more concerning is whether actually delivered DNA by HD machines matches the prescribed concentrations [12, 16]. Previous studies have suggested that prescribed and delivered DNA concentrations may differ significantly, with reports of an overall positive bias [10, 16, 17]. In the study by Ekbåll et al. [17], setting individual dialysis machines to deliver a sodium concentration of 136 mmol/L resulted in a DNA in excess of the 136 mmol/L programmed, with a mean bias of 7.0 ± 2.1 mEq/L for one manufacturer’s dialysis machine and 3.7 ± 2.6 mEq/L for a different dialysis machine using the flame photometer method [17]. Another study tested 333 HD treatments in four facilities, which produced a central dialysate supply for all dialysis patients and reported that the greatest differences between prescribed and measured DNA concentrations were in two clinics that used one particular manufacturer’s dialysis machine compared with two clinics that used dialysis machines from a different manufacturer (least squares mean differences –3.27 and –3.77 mEq/L versus –1.44 and –1.78 mEq/L, respectively) [16].

These differences in delivered DNA and programmed DNA may potentially explain why the results, particularly of multi-centre trials, have been discordant [2] when centres use different dialysis machines [18]. More recently, automated adjustments of DNA have been introduced to achieve ‘zero diffusive balance’ using conductivity balance as a surrogate of sodium concentration [19]. As such, we wished to determine whether there were differences in delivered DNA and programmed DNA concentration in our dialysis centres with different dialysis machines.

MATERIALS AND METHODS

We conducted a quality improvement study in three dialysis facilities: Royal Free Hospital, Edgware Community Hospital and Tottenham Hale Kidney and Diabetes Centre under the care of University College London, Department of Renal Medicine. Fresh dialysate samples were obtained during priming of Fresenius HD 4008H (F4008H) and Fresenius haemodiafiltration 5008S (F5008S) machines (Fresenius Medical Care, Bad Homburg, Germany) and B-Braun haemodiafiltration machines Dialog+ (BB; B-Braun, Melsungen, Germany). Dialysate was formed by combining ultrapure dialysis water with sodium bicarbonate (Bibag, Fresenius Medical Care) and an acid electrolyte concentrate (Kimal, Uxbridge, UK) within the HD machine. The final dialysate composition was set to deliver different sodium concentrations (135, 136, 140 and 145 mmol/L) in combination with varying potassium concentrations (1, 2 or 3 mmol/L) and calcium (1.0, 1.25, 1.5 and 1.75 mmol/L), with fixed concentrations of magnesium (0.5 mmol/L), bicarbonate (32 mmol/L), acetate (3 mmol/L) and glucose (5.5 mmol/L).

DNA was measured by three methods: flame photometry (FP), indirect ISE and ion chromatography (IC). FP (Flame Photometer IL 943, Instrumentation Laboratory, Warrington, UK) used the appropriate calibration standards and Roche aqueous controls and optical filters. Indirect ISE assessment used a standard multichannel biochemical analyser (Roche Modular Panalyser, Roche Diagnostics, Burgess Hill, UK). The coefficient of variation for the ISE method for measuring sodium in an aqueous solution was 1.01% for a sodium concentration of 120 mmol/L and 0.57% for a sodium concentration of 160 mmol/L and 0.4% for the flame photometer at both concentrations [17]. Ion chromatography ( Dionex ICS-1000 Ion Chromatography System, Dionex, Sunnyvale, CA, USA) used a coefficient of variation of the assay of <2% and a coefficient of all standards of 0.42%.

HD machines were regularly serviced and retested every 6 months and conductivity testing was performed using a reference instrument attached directly to the dialysis machine blue and red dialyser couplings. The reference instrument was set to read dialysate conductivity (in mS/cm) and temperature (in °C) in real time. Should the conductivity measurement differ by >0.2 mS/cm from its supposed value, a machine recalibration of the conductivity sensors was performed. If the temperature differed by –1.5/0.5 °C, a temperature sensor recalibration was performed.

Statistical analysis

Results are expressed as mean ± standard deviation (SD) or median [interquartile range (IQR)] as appropriate. Data comparison was done by one-way analysis of variance with post hoc analysis using Fisher’s least significant difference or independent samples t-test for parametric variables and Kruskal–Wallis test with Dunn’s post hoc analysis or Mann–Whitney U test for non-parametric variables. A P-value <0.05 was considered statistically significant. All statistical analyses were performed using the Statistical Package for the Social Sciences software (version 22.0; IBM, Armonk, NY, USA).

Ethics

Our retrospective audit of service development complied with the UK National Health Service Health Research Authority guidelines for clinical audit and service development, with all patient data anonymized prior to analysis (https://www.hra.nhs.uk), complied with UK National Institute for Clinical Excellence best practices (www.nice.org.uk/media/796/23/bestpracticeclinicalaudit.pdf) and registered with the University College Department of Nephrology.

RESULTS

Thirty-six Fresenius machines (18 F5008S and 18 F4008H) and 31 BB machines were tested over a total of 153 HD treatments. Machine characteristics and main outcome measures are reported in Table 1.

Overall, measured DNA with the BB machines was higher than that prescribed when measured by ISE, FP and IC (P < 0.001; Table 1). Similarly, delivered DNA by the F4008S was significantly higher than that prescribed by all methods (P < 0.05), whereas measured DNA in the F5008S was higher than that prescribed only when assessed by ISE (P < 0.001; Table 1).
Table 1. Characteristics and main outcome measures of the tested machines

| Dialysis machine characteristics | F4008H | F5008S | BB |
|----------------------------------|--------|--------|-----|
| Number of machines               | 18     | 18     | 31  |
| Number of dialysis treatments    | 31     | 53     | 69  |
| Conductivity (mS/cm)             | 14.29 ± 0.42 | 14.05 ± 0.35 | 14.25 ± 0.42 |
| Programmed DNa (mEq/L)           | 140.3 ± 3.7 | 140.3 ± 3.8 | 139.9 ± 3.8 |
| Measured DNa (mEq/L)             | 145.75 ± 4.8 | 143.5 ± 3.05 | 146.5 ± 4.6 |
| ISE                              | 143.9 ± 4.6 | 140.7 ± 2.9 | 146.7 ± 4.3 |
| FP                               | 143.6 ± 4  | 141.4 ± 3.5 | 145.4 ± 3.9 |
| Measured minus programmed DNa (mEq/L), median (IQR) | 5.5 (5–7) | 4 (2–5) | 7 (6–8) |
| ISE                              | 4 (2.25–5.75) | 1 (1–1.75) | 7 (6–8) |
| FP                               | 4 (2–5) | 1 (0.5–2) | 6 (5–7) |
| Measured potassium (mmol/L), median (IQR) | NA     | 2.2 (2.1–2.3) | 1.4 (1.1–3.6) |
| Measured calcium (mmol/L), median (IQR) | NA     | 2.7 (1.7–3.7) | 0.92 (0.36–1.52) |
| Measured magnesium (mmol/L), median (IQR) | NA     | 1.12 (1.06–1.26) | 1.05 (0.98–1.14) |

Results expressed as mean ± SD unless stated otherwise. 1.0 mEq/L sodium/potassium = 1.0 mmol/L, 2.0 mEq/L calcium/magnesium = 1.0 mmol/L. NA, not available.

We then considered the difference between the measured and prescribed DNa and the different dialysis machines. When assessed by ISE, the difference was significantly lower with the F5008S than the F4008H or BB (P < 0.05), which were similar (P = 0.19; Table 1). When assessed by FP and IC, the difference between measured and prescribed DNa differed significantly between the three machines, with the highest difference observed with the BB machines, followed by the F4008H and F5008S machines (P < 0.05; Table 1).

At a prescribed DNa of 135 and 136 mEq/L
At a prescribed DNa of 135 mEq/L, the measured DNa by all methods was consistently higher than that prescribed for the F5008S (ISE: 141.1 ± 1.7; FP: 138.5 ± 1.7; IC: 139.1 ± 2.2) and BB machines (ISE: 142.6 ± 1.3; FP: 141.8 ± 0.9; IC: 141.2 ± 0.7) (P < 0.001). DNa delivered by the BB machines was significantly higher than that of the F5008S by all methods (P < 0.05; Figure 1A).

Similarly, at a prescribed DNa of 136 mEq/L, measured DNa by all methods was consistently higher than that prescribed for the F4008H (ISE: 142.8 ± 3.65; FP: 139.7 ± 2.58; IC: 140.4 ± 1.17) and BB machines (ISE: 142.2 ± 1.25; FP: 143.4 ± 1.9; IC: 141.1 ± 1.28) and by IC for the F5008S machines (139 ± 1.4) (P < 0.05) (DNa was measured for the F5008S by IC only). DNa delivery in the BB machines was significantly higher compared with that of the F4008H machines when assessed by FP (P < 0.001), whereas the two machines were similar when assessed by ISE and IC. Compared with the F5008S machines, both the BB and F4008H machines had higher DNa IC results (P < 0.05; Figure 1B).

When we considered the median difference, measured–prescribed DNa, at a prescribed DNa of 135 mEq/L, the BB machines had significantly higher values than the F5008S machines when assessed by all methods (P < 0.05). At a prescribed DNa of 136 mEq/L, the median measured–prescribed DNa was significantly higher in the BB machines compared with the F4008H machines when assessed by FP (P = 0.004) but not when assessed by ISE or by IC (Table 2).

At a prescribed DNa of 140 mEq/L
Measured DNa by all methods for the F4008H (ISE: 144.8 ± 1.78; FP: 143.4 ± 2.4; IC: 142.7 ± 1.19) and BB machines (ISE: 146.7 ± 2.6; FP: 145.9 ± 2.08; IC: 144.95 ± 2.0) was consistently higher than that prescribed (P < 0.05), while measured DNa in the F5008S (ISE: 142.8 ± 1.95; FP: 139.8 ± 1.67; IC: 140.1 ± 2.9) was significantly higher than that prescribed when assessed by the ISE method (P ≤ 0.001). Compared with the F5008S, DNa delivery by the BB machines was significantly higher by all methods (P < 0.001) and was significantly higher by FP and IC (P < 0.05) for the F4008H; it was also higher by ISE, but did not achieve statistical significance (P = 0.051). DNa delivered by the BB machines was significantly higher than that of the F4008H by FP and IC (P < 0.05), and was also higher by ISE, yet was statistically insignificant (P = 0.06) (Figure 1C).

The median measured difference in prescribed DNa and delivered DNa was greatest for the BB machines, followed by the F4008H and the F5008S (P < 0.001), and on post hoc analysis, the difference was significant only between the BB and F5008S machines when assessed by all methods (P < 0.001; Table 3).

At a prescribed DNa of 145 mEq/L
Measured DNa in the F5008S machines (ISE: 147.4 ± 2.3; FP: 144.5 ± 1.9; IC: 145 ± 1.97) was significantly higher than that prescribed when assessed by ISE only (P = 0.017), while both the F4008H (ISE: 150.2 ± 5.26; FP: 149.4 ± 1.14; IC: 147.7 ± 4.42) and BB machines (ISE: 152.6 ± 1.36; FP: 152 ± 1.37; IC: 150.35 ± 1.53) were consistently higher than prescribed (P < 0.05). The BB machines delivered significantly higher DNa than both the F5008S and F4008H machines by all methods (P < 0.05), and similarly the differences with the F4008H machine was higher than that of the F5008S by all methods (P < 0.05) (Figure 1D).

The median measured–prescribed DNa was highest for the BB machines, followed by the F4008S and the F5008S (P < 0.001). On post hoc analysis, the difference was significant between the BB and F5008S machines when assessed by all methods (P < 0.001) and between the F4008H and F5008S machines when assessed by IC (P = 0.045; Table 3).
Table 2. The difference between measured and programmed DNa at 135 and 136 mEq/L

| Na measurement method                  | At programmed DNa 135 mEq/L* | At programmed DNa 136 mEq/L** |
|----------------------------------------|------------------------------|------------------------------|
| ISE measured minus programmed DNa     | F4008H (n = 10) | F5008S (n = 10) | BB (n = 10) | F4008H (n = 10) | F5008S (n = 10) | BB (n = 11) |
| FP measured minus programmed DNa      | NA                           | 6 (4.75–7.25) | 7.5 (7–9) | 5.5 (4.75–8.75) | NA | 6 (6–7) |
| IC measured minus programmed DNa      | NA                           | 4 (1.75–5) | 7 (6–7) | 4.5 (0.75–6) | NA | 8 (7–8) |

Results expressed as median (IQR).

*P < 0.05 between F5008S/BB when DNa measured by all methods.

**P = 0.004 between F4008H/BB when DNa measured by FP.

NA, not available.

Table 3. The difference between measured and programmed DNa at a programmed DNa of 140 or 145 mEq/L

| Na measurement method                  | At prescribed DNa 140 mEq/L* | At prescribed DNa 145 mEq/L** |
|----------------------------------------|------------------------------|------------------------------|
| ISE measured minus programmed DNa     | F4008H (n = 11) | F5008S (n = 21) | BB (n = 20) | F4008H (n = 10) | F5008S (n = 17) | BB (n = 20) |
| FP measured minus programmed DNa      | 5 (1–5.5) | 0 (–1–1) | 6 (3.25–6) | 7 (1–8.5) | 2.5 (0.75–4) | 8 (6.5–9) |
| IC measured minus programmed DNa      | 2 (2–4) | 1 (–1–2) | 6 (3.25–6) | 4.5 (0.25–5.25) | 1 (–1.5–1.5) | 6 (4–7) |

Results expressed as median (IQR).

*P < 0.001 between F5008S/BB when DNa measured by all methods.

**P < 0.001 between F5008S/BB by ISE, FP and IC.

P = 0.045 between F4008H/F5008S by IC.
DISCUSSION

Dialysis patients are at increased risk of cardiovascular disease and stroke. Sodium balance is an important determinant of blood pressure. As such, preventing sodium accumulation is a major objective for HD treatments. DNAs is a key component of the dialysis prescription, as it determines the diffusive sodium clearance and consequently influences the net sodium balance during a dialysis session [1, 3]. Despite the variable sodium prescription policies among different dialysis centres, alignment of the DNAs with the serum sodium concentration to achieve neutral sodium flux is considered the most appropriate practice [11, 13]. Although a higher DNAs may reduce the risk of intradialytic hypotension [20], in the longer term this may lead to increased weight gain between dialysis sessions and hypertension [21].

To be able to provide a neutral sodium balance, the programmed and delivered DNAs need to be in alignment, but a previous study reported that dialysis machines may potentially deliver more sodium than programmed [16]. In our study, we measured sodium concentration by three different methods in fresh dialysate samples obtained during priming of three different HD machines: Fresenius 4008H, Fresenius 5008S and BB. Overall, measured DNAs was greater than that programmed by all dialysis machines, at all prescribed sodium concentrations. The magnitude of bias varied between the dialysis machines and by the programmed DNA.

Overall, measured DNAs by both the F4008H and BB machines was significantly higher than that programmed measured by ISE, FP and IC, whereas measured DNAs in the F5008S was only higher than that programmed when assessed by the ISE method. The choice of programmed DNA influenced the magnitude of the difference between delivered and programmed DNAs. At lower prescribed DNAs concentrations (135 and 136 mEq/L), all three dialysis machines delivered significantly more sodium than was programmed, with the difference being greater for the BB and F4008H machines compared with the F5008S. With the higher programmed DNAs (140 and 145 mmol/L), the BB and F4008H machines again delivered significantly more sodium than was programmed, while the F5008S machines only delivered a higher DNAs when measured using the ISE method but not by IC or FP. These variances reflect the differences in the design of dialysis machines by manufacturers. Dialysis machines check the conductivity and pH after mixing ultrapure water, bicarbonate and acid concentrates of the final dialysate. Some machines then have a positive feedback loop designed to adjust the final conductivity by altering the proportion of water, bicarbonate or acid concentrate. Although the sodium concentration of the acid concentrate is entered into the dialysis machine, manufacturers are allowed a margin in error of ~2.5% in the sodium concentration. Errors in manufacture and inputting the acid concentrate sodium into the dialysis machine can lead to sodium gains during HD [10]. The F5008S was introduced to the market later than the other two dialysis machines, with software designed to automatically adjust DNAs to achieve ‘zero diffusive balance’ by using conductivity balance [19]. However, a neutral conductivity balance may lead to sodium gains, depending on potassium losses and the changes in other cations and anions, with studies reporting an increase in plasma sodium in 15 of 16 patients [19].

Our findings are in contrast to the report by Gul et al. [16], who noted that the difference between prescribed and programmed DNAs was greater with increasing DNAs concentrations. However, they tested different dialysis machines than our study, using different bicarbonate and acid concentrates and only measured DNAs by ISE. We measured DNAs by three different methods and found that the results using the ISE method were consistently higher than those measured by both FP and IC. This lends support to the previous finding that the standard ISE method used in everyday practice may overestimate sodium concentrations compared with other methods [15, 22].

Individualizing DNAs has been proposed to achieve a neutral sodium balance and minimize the risk of intradialytic hypotension [13]. A diffusive sodium gradient from dialysate to blood can potentially be avoided using isonatric dialysis, in which sodium is only removed by convection, while avoiding any alteration in plasma osmolarity [20]. The adjustment in DNAs can be manual, aligning the DNAs to the pre-dialytic plasma sodium [23] or automatically using a control algorithm integrated into the dialysis machine [19]. However, the concept of isonatric dialysis depends upon the accurate measurement of plasma sodium and delivering the programmed DNAs. Putting to one side the difficulties in accurately measuring plasma sodium [15], our results raise concerns about a potential positive sodium balance even when individualizing DNA prescriptions to be the same as pre-dialysis serum sodium. The net transfer of sodium from dialysate to the patient likely exceeds that which would have been expected based on the dialysis prescription [16].

Our study has some limitations. We measured DNAs at the start of dialysis sessions and not sodium balance during HD. Thus the effects of a higher DNAs than that programmed could be overcome by sodium losses achieved by ultrafiltration and does not necessarily imply patients would have had a positive sodium balance. However, our study may help explain why single-centre studies of reducing DNAs report a reduction in interdialytic weight gains, whereas no overall effect is reported with multicentre studies using different dialysis machines and concentrations [2]. As such, further studies are warranted to assess the net Na balance during isonatric dialysis while correlating with the difference between measured and programmed DNAs.

In conclusion, our study suggests that there is a systematic error (bias) in DNAs delivery by our HD machines. The magnitude of error varied between machines and with the DNA concentration chosen.

ACKNOWLEDGEMENTS

A.M.S. received a post-doctoral scholarship grant from the Egyptian government.

AUTHORS’ CONTRIBUTIONS

A.M.S. and A.D. contributed to the study design, sample collection, drafting the paper, its critical revision and approved the final version.

CONFLICT OF INTEREST STATEMENT

None declared.

REFERENCES

1. Lomonte C, Basile C. Do not forget to individualize dialysate sodium prescription. Nephrol Dial Transplant 2011; 26: 1126–1128
2. Tangvoraphonkhai K, Davenport A. Why does the choice of dialysate sodium concentration remain controversial? Hemodial Int 2018; 22: 435–444
3. Penne EL, Sergeyeva O. Sodium gradient: a tool to individualize dialysate sodium prescription in chronic hemodialysis patients? Blood Purif 2011; 31: 86–91
4. Munoz Mendoza J, Sun S, Chertow GM et al. Dialysate sodium and sodium gradient in maintenance hemodialysis: a neglected sodium restriction approach? Nephrol Dial Transplant 2011; 26: 1281–1287
5. Flythe JE, Causland FRM, Mc Causland FR. Dialysate sodium: rationale for evolution over time. Semin Dial 2017; 30: 99–111
6. Shah A, Davenport A. Does a reduction in dialysate sodium improve blood pressure control in haemodialysis patients? Nephron Extra 2017; 7: 10–17
7. Thijssen S, Raimann JG, Usyvat LA et al. The evils of intradialytic sodium loading. Contrib Nephrol 2011; 171: 84–91
8. Davenport A, Cox C, Thuraisingham R. The importance of dialysate sodium concentration in determining interdialytic weight gains in chronic haemodialysis patients: the PanThames Renal Audit. Int J Artif Organs 2008; 31: 411–417
9. Davenport A. Audit of the effect of dialysate sodium concentration on inter-dialytic weight gains and blood pressure control in chronic haemodialysis patients. Nephron Clin Pract 2006; 104: c120–c125
10. Sandhu E, Crawford C, Davenport A. Weight gains and increased blood pressure in outpatient haemodialysis patients due to change in acid dialysate concentrate supplier. Int J Artif Organs 2012; 35: 642–647
11. Hecking M, Karaboyas A, Saran R et al. Dialysate sodium concentration and the association with intradialytic weight gain, hospitalization, and mortality. Clin J Am Soc Nephrol 2012; 7: 92–100
12. Weiner DE, Brunelli SM, Hunt A et al. Improving clinical outcomes among hemodialysis patients: a proposal for a “volume first” approach from the chief medical officers of US dialysis providers. Am J Kidney Dis 2014; 64: 685–695
13. de Paula FM, Peixoto AJ, Pinto LV et al. Clinical consequences of an individualized dialysate sodium prescription in hemodialysis patients. Kidney Int 2004; 66: 1232–1238
14. Thijssen S, Raimann JG, Usyvat LA et al. The evils of intradialytic sodium loading. Contrib Nephrol 2011; 171: 84–91
15. Spichiger UE, Rumpf G, Haase E et al. Chemical sensors in medical use: ion-selective electrodes, limitations and potentials. Schweiz Med Wochenschr 1991; 121: 1875–1879
16. Gul A, Miskulin DC, Paine SS et al. Comparison of prescribed and measured dialysate sodium: a quality improvement project. Am J Kidney Dis 2016; 67: 439–445
17. Ekbal NJ, Consalus A, Persaud J et al. Reliability of delivered dialysate sodium concentration. Hemodial Int 2016; 20(Suppl 1): S2–S6
18. Mohamed A, Davenport A. Comparison of methods to estimate haemodialysis urea clearance. Int J Artif Organs 2018; 41: 371–377
19. Kuhlmann U, Maierhofer A, Canaud B et al. Zero diffusive sodium balance in hemodialysis provided by an algorithm-based electrolyte balancing controller: a proof of principle clinical study. Artif Organs 2019; 43: 150–158
20. Donati G, Ursino M, Spazzoli A et al. Sodium prescription in the prevention of intradialytic hypotension: new insights into an old concept. Blood Purif 2018; 45: 61–70
21. Raimann JG, Thijssen S, Usyvat LA et al. Sodium alignment in clinical practice—implementation and implications. Semin Dial 2011; 24: 587–592
22. Persaud J, Thomas M, Davenport A. Indirect ion selective electrode methods potentially overestimate peritoneal dialysate sodium losses. Ther Apher Dial 2014; 18: 321–325
23. Raimann JG, Ficociello LH, Usyvat LA et al. Effects of dialysate to serum sodium (Na+) alignment in chronic hemodialysis (HD) patients: retrospective cohort study from a quality improvement project. BMC Nephrol 2018; 19: 75